Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28908000 | 0.79 | ALDH1A1 (0.42) | ALDH1A1CES1CA1CA2TDP1 | |
| SCHEMBL3994803 | 0.77 | APEX1 (0.44) | ALDH1A1HPGDTDP1TSHRMEN1 | |
| SCHEMBL3295797 | 0.71 | LMNA (0.39) | ALDH1A1HPGDTDP1TSHR | |
| SCHEMBL509243 | 0.69 | ALDH1A1 (0.40) | ALDH1A1HPGDL3MBTL1MEN1KMT2A | |
| SCHEMBL3282450 | 0.69 | NPC1 (0.43) | ALDH1A1HPGDL3MBTL1MEN1KMT2A | |
| SCHEMBL2059687 | 0.69 | ALDH1A1 (0.38) | ALDH1A1HPGDL3MBTL1MEN1KMT2A | |
| SCHEMBL1160372 | 0.67 | ALDH1A1 (0.46) | ALDH1A1HPGDL3MBTL1TSHRMEN1 | |
| SCHEMBL28260884 | 0.66 | — | — | |
| SCHEMBL28160476 | 0.66 | — | — | |
| SCHEMBL9918707 | 0.66 | CA12 (0.35) | ALDH1A1HPGDL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376492-B1 | 3,4 DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-04-08 | — | — | EP | disclosed |
| US-8981092-B2 | Substituted 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-ones as modulators of protein kinase activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-20130137696-A1 | 3,4-DIHYDRO-2H-PYRROLO[1,2-A]PYRAZIN-1-ONE DERIVATIVES FOR THE MODULATION OF THE ACTIVITY OF PROTEIN KINASES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-05-30 | — | — | US | disclosed |
| US-8394802-B2 | 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one derivatives for the modulation of the activity of protein kinases | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-03-12 | — | — | US | disclosed |
| EP-2376492-A1 | 3,4 DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-19 | — | — | EP | disclosed |
| US-20110251179-A1 | 3,4-DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2011-10-13 | — | — | US | disclosed |
| WO-2010031816-A1 | 3,4 DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-25 | — | — | WO | disclosed |
| US-6051243-A | USEFUL IN THE TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL CONDITIONS ASSOCIATED WITH A KERATINIZATION DISORDER, DERMATOLOGICAL CONDITIONS (AND THE LIKE) INCLUDING AN INFLAMMATORY AND/OR IMMUNOALLERGIC COMPONENT | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 2000-04-18 | — | — | US | disclosed |
| US-5709867-A | TREATMENT OF DERMATOLOGICAL, RHEUMATIC, RESPIRATORY, CARDIOVASCULAR, AND OPHTHALMOLOGICAL DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-01-20 | — | — | US | disclosed |
| EP-0661260-B1 | New bi-aromatic compounds derived from amides pharmaceutical compositions and cosmetic compositions containing them and their use | CIRD GALDERMA (FR) | 1997-03-12 | — | — | EP | disclosed |
| EP-0661260-A1 | New bi-aromatic compounds derived from amides pharmaceutical compositions and cosmetic compositions containing them and their use | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251179-A1 | 3,4-DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES | PDK1, PDPK1, CDK3 | ALDH1A1 1974/4885HPGD 2407/4885CES1 4019/4885 |
| US-20130137696-A1 | 3,4-DIHYDRO-2H-PYRROLO[1,2-A]PYRAZIN-1-ONE DERIVATIVES FOR THE MODULATION OF THE ACTIVITY OF PROTEIN KINASES | MAP3K15, MAP3K1, MAP3K3 | ALDH1A1 2930/4885HPGD 2674/4885CES1 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.